Inhaled iloprost for therapy in pulmonary arterial hypertension
- PMID: 21510725
- DOI: 10.1586/ers.11.14
Inhaled iloprost for therapy in pulmonary arterial hypertension
Abstract
Iloprost (Ventavis, Bayer Schering Pharma, Germany) is a synthetic prostacyclin that is used in its inhalative form for the therapy of pulmonary arterial hypertension. Long-term therapy can increase exercise capacity and quality of life. The use of modern nebulizers especially designed for the administration of iloprost guarantees the pulmonary deposition of the required doses and systematically minimizes side effects. Regarding existing data, inhalative iloprost acts in effective and safe combination with other classes of medication; indeed, such combination therapy is frequently necessary in pulmonary arterial hypertension.
Similar articles
-
Rapid transition from inhaled iloprost to inhaled treprostinil in patients with pulmonary arterial hypertension.Cardiovasc Ther. 2013 Feb;31(1):38-44. doi: 10.1111/1755-5922.12008. Cardiovasc Ther. 2013. PMID: 22970909 Free PMC article. Clinical Trial.
-
Inhaled iloprost in pulmonary arterial hypertension.Ann Pharmacother. 2005 Jul-Aug;39(7-8):1265-74. doi: 10.1345/aph.1E575. Ann Pharmacother. 2005. PMID: 15976392 Review.
-
[Prostacyclin and iloprost in aerosol form in severe pulmonary hypertension].Pneumologie. 1998 Jan;52(1):3-7. Pneumologie. 1998. PMID: 9540363 German. No abstract available.
-
[Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to pulmonary fibrosis].Pneumologie. 2000 Mar;54(3):133-42. doi: 10.1055/s-2000-9076. Pneumologie. 2000. PMID: 10783653 Clinical Trial. German.
-
lloprost delivered via the BREELIBTM nebulizer: a review of the clinical evidence for efficacy and safety.Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619835497. doi: 10.1177/1753466619835497. Ther Adv Respir Dis. 2019. PMID: 30874487 Free PMC article. Review.
Cited by
-
[Acute response of right ventricular function to iloprost inhalations in patients with pulmonary arterial hypertension: preliminary evaluation with cardiac magnetic resonance imaging].Zhongguo Fei Ai Za Zhi. 2015 Mar;18(3):167-71. doi: 10.3779/j.issn.1009-3419.2015.03.07. Zhongguo Fei Ai Za Zhi. 2015. PMID: 25800574 Free PMC article. Chinese.
-
An Update on Advancements and Challenges in Inhalational Drug Delivery for Pulmonary Arterial Hypertension.Molecules. 2022 May 29;27(11):3490. doi: 10.3390/molecules27113490. Molecules. 2022. PMID: 35684428 Free PMC article. Review.
-
Inhaled pulmonary vasodilators: a narrative review.Ann Transl Med. 2021 Apr;9(7):597. doi: 10.21037/atm-20-4895. Ann Transl Med. 2021. PMID: 33987295 Free PMC article. Review.
-
Effect of inhaled iloprost on the exercise function of Fontan patients: a demonstration of concept.Int J Cardiol. 2013 Oct 3;168(3):2435-40. doi: 10.1016/j.ijcard.2013.03.014. Epub 2013 Mar 29. Int J Cardiol. 2013. PMID: 23545150 Free PMC article. Clinical Trial.
-
Systematic Review of Health-Related Quality of Life in Patients with Pulmonary Arterial Hypertension.Pharmacoeconomics. 2016 Aug;34(8):751-70. doi: 10.1007/s40273-016-0395-y. Pharmacoeconomics. 2016. PMID: 26951248 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical